A new year's resolution to resolve atrial fibrillation: Resolvin D1 emerges as a powerful target against post-MI atrial remodelling

Cardiovasc Res. 2024 Mar 30;120(4):329-330. doi: 10.1093/cvr/cvae039.

Authors

Juan J Velasco¹, Fadi G Akar^{1

2}

Affiliations

¹ Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, 789 Howard Ave, New Haven, CT 06519, USA.
² Department of Biomedical Engineering, Yale University Schools of Engineering and Applied Sciences, Electro-biology and Arrhythmia Therapeutics Laboratory, 300 George Street, 793-748C, New Haven, CT 06511, USA.

PMID: 38387430
PMCID: PMC10981522 (available on 2025-02-22)
DOI: 10.1093/cvr/cvae039

No abstract available

Publication types

Editorial
Comment

MeSH terms

Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / physiopathology
Atrial Remodeling*
Docosahexaenoic Acids*
Humans
Inflammation
Ventricular Dysfunction, Left*

Substances

resolvin D1
Docosahexaenoic Acids

Grants and funding